Price
41.72
-0.67%Market Cap
₹25.15 Cr
Traded: ₹0.01 Cr (0.03%) 0.0x
Free Float: ₹6.43 Cr (0.11% of FF traded)
Volume · 60D trend
1.76 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +36.0% | -- | -- | -- | -- | -- |
| ROE | -- | -- | -- | -- | -- | -- |
| Return | +23.0% | +61.0% | -- | -- | -- | Accelerating |
| Profit | -- | -- | -- | -- | -79.0% | -- |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Profit | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | 0 | 0 | -0 | 0 | 0 |
| OPM % | -17.9% | -8.3% | -34.3% | -15.0% | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | 0 | 0 | -0 | 0 | 0 |
| Tax % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -- | -- | -- | 0.0% | -- | -- |
| Net Profit | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | 0 | 0 | -0 | 0 | 0 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | -0.1 | -0.1 | -0.1 | -0.0 | -0.0 | -0.0 | -0.0 | -0.1 | 0.0 | 0.0 | 0.0 | -0.0 | 0.0 | 0.0 |
| Sales Growth (YoY) | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Sales Growth (QoQ) | -- | 105.7% | 75.0% | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| OP Growth (YoY) | -200.0% | -50.0% | -500.0% | 57.1% | -- | -- | -- | -600.0% | -- | -- | -- | -- | -- | -- |
| OP Growth (QoQ) | -100.0% | 50.0% | -300.0% | 25.0% | 0.0% | -100.0% | 71.4% | -- | -- | -- | 100.0% | -- | -- | -- |
| Profit Growth (YoY) | -200.0% | -50.0% | -500.0% | 57.0% | -- | -- | -- | -600.0% | -- | -- | -- | -- | -- | 100.0% |
| EPS Growth (YoY) | -- | -66.7% | -400.0% | 66.7% | -- | -- | -- | -500.0% | -- | -- | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 50.0% | -400.0% | 33.3% | 0.0% | -50.0% | 66.7% | -- | -- | -- | 100.0% | -- | -- | -- |
| OP Margin | -- | -8.3% | -34.3% | -15.0% | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Margin | -- | -8.3% | -34.3% | -15.0% | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Material Cost % | 99.0% | 93.0% | 94.0% | 90.0% | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Employee Cost % | 6.0% | 8.0% | 29.0% | 20.0% | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/S | 12.96 | 16.86 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Surbhit Mukesh Shah & Others
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dhruvalkumar Patel
Clarification on Price Movement
FINANCIAL RESULT QTR1
OUTCOME OF BOARD MEETING
The Exchange has sought clarification from Rekvina Laboratories Ltd on August 12, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Allotment of Equity Shares on Preferential basis
Compliance Certificate under Reg 74(5) of SEBI (DP) Regulation 2018
Closure of Trading Window
Vivro Financial Services Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Pre-Offer Advertisement in accordance with Regulation 18(7) of The Securities and Exchange ....
Open Offer Update
Newspaper Advertisement
Vivro Financial Services Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Recommendations of the Committee of Independent Directors in accordance with Regulation 26(7) ....
Recommendations of the Committee of Independent Directors of Company under Regulation 26(7) of SEBI (SAST) Regulation, 2011
Vivro Financial Services Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Letter of Offer for the attention of the Equity Shareholders of Rekvina Laboratories Ltd ("''Target ....
We wish to inform you that the company has received a copy of the letter of offer issued by Vivro Financial Services Private Limited in relation to open offer to the Public Shareholders.
Pursuant to Reg 33 read with Part A of Schedule III of SEBI (LODR) Regulation, 2015, we hereby submitting the following: 1. Standalone Audited Financial Results for the Quarter ended ....
Standalone Audited Financial Results for the Quarter ended & Year ended on March 31, 2026 along with statement of Assets & Liabilities, Cash Flow statement & unmodified Audit Report.
Rekvina Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve Financial Result for the ....
Summary of Proceeding of EGM
Voting Results along with Scrutinizer Report
Non Applicability of Reg- 24(A) - Annual Secretarial Compliance Report
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018.
Update on Open Offer
Vivro Financial Services Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Draft Letter of Offer for the attention of the Equity Shareholders of Rekvina Laboratories ....
Trading window will remain closed with effect from, 1st April, 2026 until 48 hours after the declaration of Audited Financial Results by the Company for the Quarter & year ended on March 31, 2026.
Vivro Financial Services Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Detailed Public Statement for the attention of the Equity Shareholders of Rekvina Laboratories ....
Update on Open Offer
Shareholders Meeting - EGM 10.04.2026
Disclosure pursuant to Regulation 30 of SEBI (LODR) Reg 2015
Outcome of Board Meeting 16.03.2026
The Board of Directors of the company has approved Increase in Authorized Capital of the company.
The Company has approved Preferential Issue of Share through; 1. Swap of Shares 2. Cash Consideration as per attached details.
Vivro Financial Services Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Public Announcement for the attention of the Public Shareholders of Rekvina Laboratories Ltd ....
Rekvina Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/03/2026 ,inter alia, to consider and approve the proposal for issuance ....
Regulation 33 and Regulation 30 read with Part-A of Schedule III of SEBI (LODR) Regulation, 2015 , we hereby inform you that the Board of Directors of the Company at its meeting held on ....
Dear Sir/Madam, Pursuant to Regulation 33 and Regulation 30 read with Part-A of Schedule III of SEBI (LODR) Regulations, 2015, we hereby inform you that the Board of Directors of the ....
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 , please to informed that Mr. Chetanbhai Patel has tender his resignation from ....
Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation , 2015, we hereby inform you that the Board of Directors of the Company, at its meeting ....
Rekvina Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 ,inter alia, to consider and approve Dear Sir/Madam, Pursuant ....
Pursuant to Regulation 30 of Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that Mr. Dhruvalkumar Jayantilal ....
In compliance with the Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find enclosed herewith copy of certificate received from M/s. Purva Sharegistry ....
Trading window will be closed with effect from, January 01, 2026 until 48 hours after declaration on Un-audited Financial Results
The Paid up capital of the Company is less than Rs. 10/-(Ten) Crores and Net Worth of the Company is less than Rs. 25 /- (Twenty-Five)Crores as on 31.03.2025, so there is non-applicability ....
QTR-2 FINANCIAL RESULT
Rekvina Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve Pursuant to Regulation ....
In compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations,2018, please find enclosed herewith copy of Certificate received from M/s. Purva Sharegistry India ....
Appointment of Mr. Prateek Jain (DIN: 08611660) as an Additional Non-Executive Independent Director of the Company, pursuant to the Provisions of the Companies Act, 2013 and SEBI (Listing ....
E Voting Result along with Scrutinizer Report
Outcome - Proceeding of AGM